REFERENZEN
– Aslan D.L., Crapanzano J.P., Harshan M., Erroll M., Vakil B., Pirog E.C.: The Bethesda System 2001: recommendation for reporting of benign appearing endometrial cells in Pap tests of women age 40 years and older leads to unwarranted surveillance when followed without clinical qualifiers. Gynecol Oncol 2007; 107 (1): 86–93
– Baak J.P., Mutter G.L., Robbey Set al.: The molecular genetics and morphometry- based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005; 103: 2304–12
– Baek J.S., Lee W.H., Kang W.D., Kim S.M.: Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective? Obstet Gynecol Sci 2016; 59 (1): 24–31. doi: 10.5468/ogs.2016.59.1.24
– Beal H.N., Stone J., Beckmann M.J., McAsey M.E.: Endometrial cells identified in cervical cytology in women > or = 40 years of age: criteria for appropriate endometrial evaluation. Am J Obstet Gynecol 2007; 196 (6): 568.e1–5; discussion 568.e5–6
– Ben-Arie A., Goldchmit C., Laviv Y., Levy R., Caspi B., Huszar M., Dgani R., Hagay Z.: The malignant potential of endometrial polyps. Eur J Obstet Gynecol Reprod Biol 2004; 115 (2): 206–210
– Ben-Arie A., Tamir S., Dubnik S., Gemer O., Ben Sushan A., Dgani R., Peer G., Barnett-Griness O., Lavie O.: Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer? Int J Gynecol Cancer 2008; 18 (4): 813–819
– Blake P., Swart A.M., Orton J., Kitchener H., Whelan T., Lukka H., Eisenhauer E., Bacon M., Tu D., Parmar M.K., Armos C., Quian W. (ASTEC/ EN.5 Study Group): Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): polled trial results, systematic review, and meta analysis. Lancet 2009; 373 (9658): 137–46
– Bogani G., Murgia F., Ditto A., Raspagliesi F.: Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol 2019; 153: 676–683
– Bosse T., Peters E.E., Creutzberg C.L., Jürgenliemk-Schulz I.M., Jobsen J.J., Mens J.W. et al.: Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 2015; 51: 1742–50
– Cochrane Database, Syst Rev 2000; (2): CD001040
– Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., Sessa C.; ESMOESGO- ESTRO Endometrial Consensus Conference Working Group: ESMO- ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (1): 16–41
– Concin N., Matias-Guiu X., Vergote I., Cibula D. et al.: ESGO/ESTR/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2020; 0: 12–39
– Courneya K.S., Karvinen K.H., Campbell K.L., Pearcey R.G., Dundas G., Capstick V. et al.: Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol 2005; 97: 422–430
– Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Wárlám-Rodenhuis C.C., De Winter K.A., Lutgens L.C., van den Bergh A.C., van de Steen-Banasik E., Beerman H., van Lent M.: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: a multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355 (9213): 1404–1411
– de Boer S.M., Powell M.E., Mileshkin L., Katsaros D. et al.: Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019; 20: 1273–1285
– Dijkhuizen F.P., Mol B.W., Brölman H.A., Heintz A.P.: The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 89: 1765–72
– Egle D., Grissemann B., Zeimet A.G., Müller-Holzner E., Marth C.: Validation of intraoperative risk assessment on frozen section for surgical management of endometrial carcinoma. Gynecol Oncol 2008; 110 (3): 286– 92
– Fader A.N., Roque D.M., Siegel E., Buza N., Hui P., Abdelghany O. et al.: Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol 2018; 36: 2044–2051
– Ferguson S.E. et al.: Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 2006; 101: 322–326
– Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., Kline R., Burger R.A., Goodman A., Burks R.T.: Phase III trial of doxorubicinplus cisplatin with or without paclitaxel plus filgastrim in advancedendometrial carcinoma: a Gynecologic Oncology Group Study. J ClinOncol 2004; 22 (11): 2159–2166
– Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., VaccarelloL., Gallion H.: Phase III rancomized trial of doxorubicin plus cisplatin versus doxorubicin plus 24 h paclitaxel plus filgastrim in endometrial carcinoma: a Gynecologic Oncology Group Study. Ann Oncol 2004; 15 (8): 1173–1178
– Fotopoulou C., Kraetschell R., Dowdy S., Fujiwara K., Yaegashi N., Larusso D., Casado A., Mahner S., Herzog T.J., Kehoe S., Vergote I., Miller D.S., Marth C., Fujii S., Sehouli J.: Surgical and systemic management of endometrial cancer: an international survey. Arch Gynecol Obstet 2015; 291 (4): 897–905
– Franchi M., Ghezzi F., Melpignano M. et al.: Clinical value of intraoperative gross examination in endometrial cancer. Gynecol Oncol 2000; 76: 357–63
– Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K.: Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207 (4): 266.e1–12. doi: 10.1016/j.ajog.2012.08.011
– Gehrig P.A., Van Le L., Olatidoye B., Geradts J.: Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999; 86 (10): 2083–2089
– Gull B., Carlsson S., Karlsson B., Ylöstalo P., Milsom I., Granberg S.: Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: is it always necessary to perform an endometrial biopsy? Am J Obstet Gynecol 2000; 182 (3): 509–515
– Haltia U.-M., Bützow R., Leminen A., Loukovaara M.: FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype. J Gynecol Oncol 2014; 25 (1): 30–35
– Havrilesky L.J., Cragun L.M., Calingaert B., Alvarez Secord A., Valea F.A., Clarke-Pearson D.L, Berchuck A., Soper J.T.: The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol 2007; 104 (2): 401–405
– Hogberg T., Rosenberg P., Kristensen G. et al.: A randomized phase III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early stage high-risk endometrial cancer (NSGO-EC-9505/EORTC 55991). J Clin Oncol 2007; 25: 247s
– Hogberg T.: Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Clin Oncol (R Coll Radiol) 2008; 20 (6): 463–9
– Humber C.E., Tierney J.F., Symonds R.P., Collingwood M., Kirwan J., Williams C., Green J.A.: Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane Collaboration. Ann Oncol 2007; 18 (3): 409–420
– Johnson N., Cornes P.: Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and metaanalysis. BJOG 2007; 114: 1313–20
– Kandoth C., Schultz N., Cherniack A.D., Akbani R. et al.: Integrated genomic characterization of endometrial carcinoma. Cancer Genome Atlas Research Network. Nature 2013; 497: 67–73
– Khoury-Collado F., St. Clair C., Abu-Rustum N.R.: Sentinel Lymph Node Mapping in Endometrial Cancer: An Update. Oncologist 2016; 21: 461–466
– Kitchener H., Swart A.M., Qian Q., Amos C., Parmar M.K. & ASTEC study group: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet 2009; 373 (9658): 125–36
– Kommoss S., Reijnen C., Küsters-Vandevelde H.V.N., Prinsen C. et al.: Mismatch repair deficiency as a predictor of adjuvant radiotherapy response in endometrioid endometrial carcinoma. J Clin Oncol 2019; 37 (15_suppl): 5586
– Kommoss S. et al.: Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018; 29 (5): 1180–1188
– Kong A. et al., Cochrane Database Syst Rev 2007; (2): CD003916
– Korczynski J., Jesionek-Kupnicka D., Gottwald L., Piekarski J.: Comparison of FIGO 1989 and 2009 Recommendations on Staging of Endometrial Carcinoma: Pathologic Analysis and Cervical Status in 123 Consecutive Cases. International Journal of Gynecological Pathology 2011; 30 (4): 328–334
– Kurman R.J., Kaminski P.F., Norris H.J.: The behavior of endometrial hyperplasia. A long-term study of „untreated“ hyperplasia in 170 patients. CA Cancer J Clin 1985; 56: 403–12
– Kurnit K.C., Pedra Nobre S., Fellman B.M., Iglesias D. et al.: A comparison of adjuvant therapy approaches for patients with early-stage uterine serous carcinoma. J Clin Oncol 2019; 37 (15_suppl): 5517
– Kwon J.S., Francis J.A., Qiu F. et al.: When is a pathology review indicate in endometrial cancer? Obstet Gynecol 2007; 110: 1224
– Lacey J.V. Jr., Sherman M.E., Rush B.B. et al.: Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010; 28: 788–92
– Lambrou N.C., Gomez-Martin O., Mirhashemi R., Beach H., Salom E., Almeida- Parra Z., Penalver M.: Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 2004; 93 (3): 653–58
– Leitao M.M. Jr., Kehoe S., Barakat R.R. et al.: Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2008; 111: 244–48
– León-Castillo A., de Boer S.M., Powell M.E., Mileshkin L.R. et al.: Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol 2020; 38 (29): 3388–3397
– Lindauer J., Fowler L.M., Manolitsas T.P., Copeland L.J., Eaton L.A., Ramirez N.C., Crohn D.E.: Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer? Gynecol Oncol 2003; 91 (3): 547–551
– Lorusso D., Ferrandina G., Colombo N., Pignata S. et al.: Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 – A randomized phase II trial. Gynecol Oncol 2019; 155: 406–412
– Matei D., Filiaci V., Marcus E Randall M.E., Mutch D. et al.: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med 2019; 380 (24): 2317–2326
– Matei D., Filiaci V., Randall M. et al.: A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. J Clin Oncol 2017; 35 (Suppl.): Abstr. 5505
– May K., Bryant A., Dickinson H.O., Kehoe S., Morrison J.: Lymphadenectomy for the management of endometrial cancer. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007585. DOI: 10.1002/14651858.CD007585.pub2
– Miller D., Filiaci V., Fleming G., Mannel R., Cohn D., Matsumoto T. et al.: Randomized phase III noninferiority trial of first-line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 771
– Miller D.S., Filiaci V.L., Mannel R.S., Cohn D.E. et al.: Carboplatin and Paclitaxel for advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol 2020; 38 (33): 3841–3850
– Nasioudis D., Roy A.G., Ko E.M., Cory L. et al.: Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium. Int J Gynecol Cancer 2020; 30 (8): 1089–1094
– Nout R.A., Smit V.T., Putter H., Jürgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., van der Steen-Banasik E.M., Mens J.W., Slot A., Kroese M.C., van Bunningen B.N., Ansink A.C., van Putten W.L., Creutzberg C.L.; PORTEC Study Group: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375 (9717): 816–23
– Parslov M., Lifegaard Ø., Klintrop S., Pedersen B., Jønsson L., Eriksen P. S., Ottesen B.: Risk factors among young women with endometrial cancer: A Danish case-control study. Am J Obstet Gynecol 2000; 182: 23–29
– Pecorelli S.: Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol and Obstet 2009; 105: 103–104
– Pristauz G., Bader A.A., Regitnig P., Haas J., Winter R., Tamussino K.: How accurate is frozen section histology of pelvic lymph nodes in patients with endometrial cancer? Gynecol Oncol 2009; 115 (1): 12–17
– Randall M.E., Spirtos N.M., Dvoretsky P.: Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. J Natl Cancer Inst Monogr 1995; 19: 13–5
– Ronnett B.M., Kurman R.J.: Precursor Lesions of Endometrial Carcinoma. In: Blausteins Pathology of the female genital tract. Editor: Robert J.Kurman, Fifth Edition 2002, Springer Verlag, New York, Berlin, Heidelberg
– Rossi E.C., Kowalski L.D., Scalici J. et al.: A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017; 18: 384–392
– Silverman M.B., Roche P.C., Kho R.M., Keeney G.L., Li H., Podratz K.C.: Molecular and cytokinetic pretreatment risk in endometrial carcinoma. Gynecol Oncol 2000; 77 (1): 1–7
– Smith-Bindman R., Weiss R., Feldstein V.: How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004; 24: 558
– Statistik Austria, Österreichisches Krebsregister (Stand: Stand 02.10.2015)
– Thipgen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., Liao S.: Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004 1; 22 (19): 3902–3908
– Timmermans A., Opmeer B.C., Khan K.S. et al.: Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 160–67
– Trimble C.L., Kauderer J., Zaino R., Silverberg S., Lim P.C., Burke J.J.2nd, Alberts D., Curtin J.: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006 Feb; 106: 812–819
– Watanabe Y., Satou T., Nakai H., Etoh T., Dote K., Fujinami N., Hoshiai H.: Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol 2010; 116 (5): 1027–34
– Wright T.C. Jr., Massad S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D., for the 2006 American society for Colposcopy and Cervical Pathology – sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening test. Am J Obstet Gynecol 2007 Oct; 346–355
– Zeimet A.G., Mori H., Petru E., Polterauer S., Reinthaller A., Schauer, C. et al.: AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS). Arch Gynecol Obstet 2017; 296 (1): 123–127
– Zeimet A.G., Reimer D., Huszar M., Winterhoff B., Puistola U., Abdel-Azim S., Müller-Holzner E., Ben-Arie A., van Kempen L.C., Petru E. et al.: L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 2013; 105: 1142-1150
